Matches in SemOpenAlex for { <https://semopenalex.org/work/W4294201735> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W4294201735 endingPage "S884" @default.
- W4294201735 startingPage "S884" @default.
- W4294201735 abstract "Introduction Esketamine is a novel antidepressant approved by the FDA in 2019 in the form of an intranasal spray, recommended for Treatment-Resistant Depression (TRD). The intranasal spray system appears to be more manageable than intravenous ketamine infusion. It contains ketamine’s S- isomer which is four-fold more potent for the NMDA receptor. Objectives The aim of this case series is to describe our clinical experience in the use of Esketamine. Methods 6 TRD patients (3 men; 3 women) were recruited in San Raffaele Turro Hospital from March 2021. All patients (2 bipolar and 4 unipolar) were diagnosed with a Major Depressive Episode according to DSM-5 criteria, resistant to at least two antidepressants. Initially, Esketamine was administrated twice weekly for one month; afterward, it was administrated once weekly for a month; finally, it was administrated once weekly or every two weeks for a month. Clinical scales (HAM-D, YMRS, SSI, HAM-A, MADRS, CADSS) were administrated to assess symptoms and sides effects before and after each administration on a weekly basis. Results Three patients out of six showed an improvement in depressive symptoms: two patients had remission (final HAM-D score < 8); one patient had a clinical response (final HAM-D score < 50 % respect baseline value). Three patients withdrew the treatment: two for perceived inefficacy, after 16 and 19 administrations, one for personal reasons. Conclusions The use of Esketamine in our TRD patients showed good effectiveness and tolerability but randomized controlled clinical trials are needed to confirm our findings. Disclosure No significant relationships." @default.
- W4294201735 created "2022-09-02" @default.
- W4294201735 creator A5005659084 @default.
- W4294201735 creator A5020986794 @default.
- W4294201735 creator A5023464929 @default.
- W4294201735 creator A5023588639 @default.
- W4294201735 creator A5041886681 @default.
- W4294201735 creator A5061767388 @default.
- W4294201735 creator A5068053564 @default.
- W4294201735 date "2022-06-01" @default.
- W4294201735 modified "2023-09-26" @default.
- W4294201735 title "Clinical efficacy and tolerability of Esketamine: a case series" @default.
- W4294201735 doi "https://doi.org/10.1192/j.eurpsy.2022.2294" @default.
- W4294201735 hasPublicationYear "2022" @default.
- W4294201735 type Work @default.
- W4294201735 citedByCount "0" @default.
- W4294201735 crossrefType "journal-article" @default.
- W4294201735 hasAuthorship W4294201735A5005659084 @default.
- W4294201735 hasAuthorship W4294201735A5020986794 @default.
- W4294201735 hasAuthorship W4294201735A5023464929 @default.
- W4294201735 hasAuthorship W4294201735A5023588639 @default.
- W4294201735 hasAuthorship W4294201735A5041886681 @default.
- W4294201735 hasAuthorship W4294201735A5061767388 @default.
- W4294201735 hasAuthorship W4294201735A5068053564 @default.
- W4294201735 hasBestOaLocation W42942017351 @default.
- W4294201735 hasConcept C118552586 @default.
- W4294201735 hasConcept C126322002 @default.
- W4294201735 hasConcept C139719470 @default.
- W4294201735 hasConcept C162324750 @default.
- W4294201735 hasConcept C197934379 @default.
- W4294201735 hasConcept C2776867660 @default.
- W4294201735 hasConcept C2777342061 @default.
- W4294201735 hasConcept C2778375690 @default.
- W4294201735 hasConcept C2779177272 @default.
- W4294201735 hasConcept C2780795376 @default.
- W4294201735 hasConcept C2781161787 @default.
- W4294201735 hasConcept C2992053201 @default.
- W4294201735 hasConcept C3019858935 @default.
- W4294201735 hasConcept C42219234 @default.
- W4294201735 hasConcept C535046627 @default.
- W4294201735 hasConcept C558461103 @default.
- W4294201735 hasConcept C71924100 @default.
- W4294201735 hasConceptScore W4294201735C118552586 @default.
- W4294201735 hasConceptScore W4294201735C126322002 @default.
- W4294201735 hasConceptScore W4294201735C139719470 @default.
- W4294201735 hasConceptScore W4294201735C162324750 @default.
- W4294201735 hasConceptScore W4294201735C197934379 @default.
- W4294201735 hasConceptScore W4294201735C2776867660 @default.
- W4294201735 hasConceptScore W4294201735C2777342061 @default.
- W4294201735 hasConceptScore W4294201735C2778375690 @default.
- W4294201735 hasConceptScore W4294201735C2779177272 @default.
- W4294201735 hasConceptScore W4294201735C2780795376 @default.
- W4294201735 hasConceptScore W4294201735C2781161787 @default.
- W4294201735 hasConceptScore W4294201735C2992053201 @default.
- W4294201735 hasConceptScore W4294201735C3019858935 @default.
- W4294201735 hasConceptScore W4294201735C42219234 @default.
- W4294201735 hasConceptScore W4294201735C535046627 @default.
- W4294201735 hasConceptScore W4294201735C558461103 @default.
- W4294201735 hasConceptScore W4294201735C71924100 @default.
- W4294201735 hasIssue "S1" @default.
- W4294201735 hasLocation W42942017351 @default.
- W4294201735 hasLocation W42942017352 @default.
- W4294201735 hasOpenAccess W4294201735 @default.
- W4294201735 hasPrimaryLocation W42942017351 @default.
- W4294201735 hasRelatedWork W2006017160 @default.
- W4294201735 hasRelatedWork W2099749043 @default.
- W4294201735 hasRelatedWork W2765666700 @default.
- W4294201735 hasRelatedWork W2798054587 @default.
- W4294201735 hasRelatedWork W2801076592 @default.
- W4294201735 hasRelatedWork W2945361245 @default.
- W4294201735 hasRelatedWork W3203712530 @default.
- W4294201735 hasRelatedWork W4224982601 @default.
- W4294201735 hasRelatedWork W4234395868 @default.
- W4294201735 hasRelatedWork W4294201735 @default.
- W4294201735 hasVolume "65" @default.
- W4294201735 isParatext "false" @default.
- W4294201735 isRetracted "false" @default.
- W4294201735 workType "article" @default.